Review of NICE Technology Appraisal Guidance No.215: Pazopanib for the first-line treatment of advanced and/or metastatic renal cell carcinoma

Proposal to move the existing guidance to the static list

The consideration of a review of the above guidance was set to be completed by December 2013, once the data from the COMPARZ trial became available.

This is the time at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full review appraisal.

Following the publication of the results of the COMPARZ trial, TA215 was re-issued in August 2013.  Part B of the Patient Access Scheme in the original guidance will now not be activated, and any references to this have been removed from the guidance.

There is no new evidence available that is likely to lead to a change in the existing recommendations.  There is no change to the licensed indication for pazopanib and no new drugs for the same indication have been referred by the Department of Health for appraisal.  Consequently we propose thatthe newly re-issued TA215 guidance should move to the static list of technology appraisals.

Topics on the static list may be transferred back to the active list for further appraisal if new evidence becomes available that is likely to have a material effect on the last guidance issued.

In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which will help us decide the best way to update this guidance.  Please see appendix A for a full list of the organisations we have contacted. 

September 2013